Although chemoimmunotherapy is effective as a first-line therapy in CLL patients without TP53 dysfunction and long-term remissions after fludarabine/cyclophosphamide/rituximab (FCR) in IGHV-mutated patients may indicate a potential cure of some patients [7], CLL is normally considered incurable. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.